Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma

Int J Urol. 2004 Oct;11(10):906-8. doi: 10.1111/j.1442-2042.2004.00914.x.

Abstract

Various toxicities have been observed during the treatment of advanced renal cell carcinoma with interferon-alpha (IFN-alpha) and/or interleukin-2 (IL-2). We report a case of severe anemia, which responded well to steroid therapy, in a patient receiving IL-2 plus IFN-alpha for metastatic renal cell carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Anemia / chemically induced*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary
  • Disease Progression
  • Female
  • Humans
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / adverse effects
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / adverse effects
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology
  • Middle Aged
  • Severity of Illness Index

Substances

  • Interferon-alpha
  • Interleukin-2